Download answer_key/T02.json from hedwigai/model-bench-v2: direct link, hf CLI and curl.
- Browser
- Download file 8.34 kB
-
https://huggingface.co/datasets/hedwigai/model-bench-v2/resolve/main/answer_key/T02.json
- Command line
-
hf download hf://datasets/hedwigai/model-bench-v2/answer_key/T02.json
-
curl -L -o T02.json https://huggingface.co/datasets/hedwigai/model-bench-v2/resolve/main/answer_key/T02.json
8.34 kB
| { | |
| "task": "T02 FDA CDER novel approvals Sept 2026", | |
| "expected_count": 9, | |
| "scoring": { | |
| "row_correct_if": "brand + active ingredient + date exact; indication substantively matches", | |
| "note": "The FDA page lists rows newest-first; Emcitate is row 45 and sits in a transposed block the `fda approvals` program dropped in the pilot (bugs.md #1). openFDA shows exactly 9 ORIG approvals with class 'Type 1 - New Molecular Entity' in Sept 2026, matching the page. Excluded on purpose: Type 2/5 NDAs (Lamlique, Bexlutry, Omcazio, Zueino, Degevma) and BLA Garzulys (no NME class) — not on CDER's novel list." | |
| }, | |
| "rows": [ | |
| { | |
| "brand": "Zanvastro", | |
| "active ingredient": "zilganersen", | |
| "approved on": "2026-09-03", | |
| "approved to treat": "Alexander disease in pediatric and adult patients", | |
| "application": "NDA220210", | |
| "sponsor": "Ionis", | |
| "sources": [ | |
| { | |
| "kind": "primary", | |
| "url": "https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026", | |
| "quote": "Row 37: Zanvastro | zilganersen | 9/3/2026" | |
| }, | |
| { | |
| "kind": "other", | |
| "url": "https://api.fda.gov/drug/drugsfda.json?search=products.brand_name:%22ZANVASTRO%22", | |
| "quote": "NDA220210 ... submission_type ORIG, submission_status AP, submission_status_date 20260903, submission_class_code_description 'Type 1 - New Molecular Entity'" | |
| } | |
| ] | |
| }, | |
| { | |
| "brand": "Etcamah", | |
| "active ingredient": "camizestrant", | |
| "approved on": "2026-09-04", | |
| "approved to treat": "HR-positive, HER2-negative (ESR1-mutated) locally advanced or metastatic breast cancer", | |
| "application": "NDA220359", | |
| "sponsor": "AstraZeneca", | |
| "sources": [ | |
| { | |
| "kind": "primary", | |
| "url": "https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026", | |
| "quote": "Row 38: Etcamah | camizestrant | 9/4/2026" | |
| }, | |
| { | |
| "kind": "other", | |
| "url": "https://api.fda.gov/drug/drugsfda.json?search=products.brand_name:%22ETCAMAH%22", | |
| "quote": "NDA220359 ... submission_type ORIG, submission_status AP, submission_status_date 20260904, submission_class_code_description 'Type 1 - New Molecular Entity'" | |
| } | |
| ] | |
| }, | |
| { | |
| "brand": "Isembyld", | |
| "active ingredient": "apitegromab-mstn", | |
| "approved on": "2026-09-11", | |
| "approved to treat": "spinal muscular atrophy in adults and pediatric patients 2 years and older", | |
| "application": "BLA761463", | |
| "sponsor": "Scholar Rock", | |
| "sources": [ | |
| { | |
| "kind": "primary", | |
| "url": "https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026", | |
| "quote": "Row 39: Isembyld | apitegromab-mstn | 9/11/2026" | |
| }, | |
| { | |
| "kind": "other", | |
| "url": "https://api.fda.gov/drug/drugsfda.json?search=products.brand_name:%22ISEMBYLD%22", | |
| "quote": "BLA761463 ... submission_type ORIG, submission_status AP, submission_status_date 20260911, submission_class_code_description 'Type 1 - New Molecular Entity'" | |
| } | |
| ] | |
| }, | |
| { | |
| "brand": "Pixclara", | |
| "active ingredient": "floretyrosine F 18", | |
| "approved on": "2026-09-11", | |
| "approved to treat": "PET imaging to differentiate recurrent or progressive glioma from treatment-related change", | |
| "application": "NDA218592", | |
| "sponsor": "Telix", | |
| "sources": [ | |
| { | |
| "kind": "primary", | |
| "url": "https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026", | |
| "quote": "Row 40: Pixclara | floretyrosine F 18 | 9/11/2026" | |
| }, | |
| { | |
| "kind": "other", | |
| "url": "https://api.fda.gov/drug/drugsfda.json?search=products.brand_name:%22PIXCLARA%22", | |
| "quote": "NDA218592 ... submission_type ORIG, submission_status AP, submission_status_date 20260911, submission_class_code_description 'Type 1 - New Molecular Entity'" | |
| } | |
| ] | |
| }, | |
| { | |
| "brand": "Onswik", | |
| "active ingredient": "insulin efsitora alfa-gobe", | |
| "approved on": "2026-09-23", | |
| "approved to treat": "glycemic control in adults with type 2 diabetes mellitus", | |
| "application": "BLA761408", | |
| "sponsor": "Eli Lilly", | |
| "sources": [ | |
| { | |
| "kind": "primary", | |
| "url": "https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026", | |
| "quote": "Row 41: Onswik | insulin efsitora alfa-gobe | 9/23/2026" | |
| }, | |
| { | |
| "kind": "other", | |
| "url": "https://api.fda.gov/drug/drugsfda.json?search=products.brand_name:%22ONSWIK%22", | |
| "quote": "BLA761408 ... submission_type ORIG, submission_status AP, submission_status_date 20260923, submission_class_code_description 'Type 1 - New Molecular Entity'" | |
| } | |
| ] | |
| }, | |
| { | |
| "brand": "Lyrfigtu", | |
| "active ingredient": "lirafugratinib", | |
| "approved on": "2026-09-23", | |
| "approved to treat": "previously treated unresectable, locally advanced or metastatic cholangiocarcinoma with an FGFR2 alteration", | |
| "application": "NDA220425", | |
| "sponsor": "Elevar", | |
| "sources": [ | |
| { | |
| "kind": "primary", | |
| "url": "https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026", | |
| "quote": "Row 42: Lyrfigtu | lirafugratinib | 9/23/2026" | |
| }, | |
| { | |
| "kind": "other", | |
| "url": "https://api.fda.gov/drug/drugsfda.json?search=products.brand_name:%22LYRFIGTU%22", | |
| "quote": "NDA220425 ... submission_type ORIG, submission_status AP, submission_status_date 20260923, submission_class_code_description 'Type 1 - New Molecular Entity'" | |
| } | |
| ] | |
| }, | |
| { | |
| "brand": "Juvmo", | |
| "active ingredient": "tavapadon", | |
| "approved on": "2026-09-25", | |
| "approved to treat": "Parkinson's disease in adults", | |
| "application": "NDA220415", | |
| "sponsor": "AbbVie", | |
| "sources": [ | |
| { | |
| "kind": "primary", | |
| "url": "https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026", | |
| "quote": "Row 43: Juvmo | tavapadon | 9/25/2026" | |
| }, | |
| { | |
| "kind": "other", | |
| "url": "https://api.fda.gov/drug/drugsfda.json?search=products.brand_name:%22JUVMO%22", | |
| "quote": "NDA220415 ... submission_type ORIG, submission_status AP, submission_status_date 20260925, submission_class_code_description 'Type 1 - New Molecular Entity'" | |
| } | |
| ] | |
| }, | |
| { | |
| "brand": "Atebrioz", | |
| "active ingredient": "zilurgisertib", | |
| "approved on": "2026-09-25", | |
| "approved to treat": "reduce new heterotopic ossification in fibrodysplasia ossificans progressiva (FOP), adults and pediatric patients 12+", | |
| "application": "NDA221198", | |
| "sponsor": "Mirum", | |
| "sources": [ | |
| { | |
| "kind": "primary", | |
| "url": "https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026", | |
| "quote": "Row 44: Atebrioz | zilurgisertib | 9/25/2026" | |
| }, | |
| { | |
| "kind": "other", | |
| "url": "https://api.fda.gov/drug/drugsfda.json?search=products.brand_name:%22ATEBRIOZ%22", | |
| "quote": "NDA221198 ... submission_type ORIG, submission_status AP, submission_status_date 20260925, submission_class_code_description 'Type 1 - New Molecular Entity'" | |
| } | |
| ] | |
| }, | |
| { | |
| "brand": "Emcitate", | |
| "active ingredient": "tiratricol", | |
| "approved on": "2026-09-28", | |
| "approved to treat": "peripheral thyrotoxicosis in patients with MCT8 deficiency", | |
| "application": "NDA220963", | |
| "sponsor": "Rare Thyroid", | |
| "sources": [ | |
| { | |
| "kind": "primary", | |
| "url": "https://www.fda.gov/drugs/novel-drug-approvals-fda/novel-drug-approvals-2026", | |
| "quote": "Row 45: Emcitate | tiratricol | 9/28/2026" | |
| }, | |
| { | |
| "kind": "other", | |
| "url": "https://api.fda.gov/drug/drugsfda.json?search=products.brand_name:%22EMCITATE%22", | |
| "quote": "NDA220963 ... submission_type ORIG, submission_status AP, submission_status_date 20260928, submission_class_code_description 'Type 1 - New Molecular Entity'" | |
| } | |
| ] | |
| } | |
| ], | |
| "frozen": "2026-11-12" | |
| } |